The World’s Definitive Degrader & Proximity-Based Drugs Event

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone.

However, following the risk-averse funding environment of 2025, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it is designed to help you discover the best novel targets, optimize your degrader profile, attract funding and partnerships, and accelerate your pipelines to the clinic and beyond.

Uniting leaders from the likes of Arvinas, Revolution Medicines, Foghorn Therapeutics, BMS, Amgen, C4 Therapeutics, Neomorph and more, this end-to-end forum is designed to equip you with the data, insights and connections to advance your own induced proximity pipeline and transform therapeutic strategies across oncology, immunology and neurodegeneration.